Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...
Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...
StockStory.org on MSN6d
Why Fortrea (FTRE) Shares Are Plunging TodayWhat Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after ...
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what ...
Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...
Smith announces an investigation on behalf of Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) investors concerning the Company’s possible violations of federal ...
Research analysts at William Blair cut their Q4 2025 earnings estimates for Fortrea in a research report issued to clients ...
Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Fortrea Holdings Inc. (FTRE – Research Report) yesterday and set a ...
6d
Zacks Investment Research on MSNFortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Miss EstimatesFortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.19 per share a year ago.
In a report released today, Max Smock from William Blair maintained a Hold rating on Fortrea Holdings Inc. (FTRE – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results